By Business/Source
Currency:CHF
2024/FY
Stock NameRevenueRatio
Discovery, development and prospective commercialization of a new class of biopharmaceutical4.97M100.00%
By Country/Region
Currency:CHF
2024/FY
Stock NameRevenueRatio
Switzerland4.97M100.00%